| Dr Daniel P Bouknight, MD | |
|
1 Wellness Blvd Ste 106, Irmo, SC 29063-2872 | |
| (803) 888-2282 | |
| (803) 888-2299 |
| Full Name | Dr Daniel P Bouknight |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 31 Years |
| Location | 1 Wellness Blvd Ste 106, Irmo, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427057009 | NPI | - | NPPES |
| 17456 | Other | SC | SC LICENCE |
| 174563 | Medicaid | SC |
| Facility Name | Location | Facility Type |
|---|---|---|
| Amedisys Home Health Of Lexington | Lexington, SC | Home health agency |
| Prisma Health Baptist Parkridge | Columbia, SC | Hospital |
| Lexington Medical Center | West columbia, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| South Carolina Internal Medicine Associates And Rehabilitation,l.l.c. | 1759362072 | 26 |
| Carolina Cardiology And Vascular Associates Llc | 3375899131 | 4 |
News Archive
Nearly 15,000 UK consumers answered questions about their hearing and their knowledge of hearing aids in the most comprehensive and largest survey ever undertaken in this field. The EuroTrak UK study will provide invaluable data for GPs, the NHS, Department of Health and the audiology profession. This study is now being publicised by The British Hearing Aid Manufacturers Association (BHAMA).
In a rare distinction for one university, neuroimaging world leaders and USC Professors Arthur Toga and Paul Thompson will receive two major research center awards to advance their exploration of the human brain.
Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.
Scientists from the National Institutes of Health and University of Chicago have found a promising treatment method that in laboratory mice reduces the severity of skin and soft-tissue damage caused by USA300, the leading cause of community-associated Staphylococcus aureus infections in the United States.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.
› Verified 4 days ago
| Entity Name | Augustine Health Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821051392 PECOS PAC ID: 8628973443 Enrollment ID: O20031204000917 |
News Archive
Nearly 15,000 UK consumers answered questions about their hearing and their knowledge of hearing aids in the most comprehensive and largest survey ever undertaken in this field. The EuroTrak UK study will provide invaluable data for GPs, the NHS, Department of Health and the audiology profession. This study is now being publicised by The British Hearing Aid Manufacturers Association (BHAMA).
In a rare distinction for one university, neuroimaging world leaders and USC Professors Arthur Toga and Paul Thompson will receive two major research center awards to advance their exploration of the human brain.
Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.
Scientists from the National Institutes of Health and University of Chicago have found a promising treatment method that in laboratory mice reduces the severity of skin and soft-tissue damage caused by USA300, the leading cause of community-associated Staphylococcus aureus infections in the United States.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.
› Verified 4 days ago
| Entity Name | South Carolina Internal Medicine Associates And Rehabilitation,l.l.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760483382 PECOS PAC ID: 1759362072 Enrollment ID: O20040525000145 |
News Archive
Nearly 15,000 UK consumers answered questions about their hearing and their knowledge of hearing aids in the most comprehensive and largest survey ever undertaken in this field. The EuroTrak UK study will provide invaluable data for GPs, the NHS, Department of Health and the audiology profession. This study is now being publicised by The British Hearing Aid Manufacturers Association (BHAMA).
In a rare distinction for one university, neuroimaging world leaders and USC Professors Arthur Toga and Paul Thompson will receive two major research center awards to advance their exploration of the human brain.
Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.
Scientists from the National Institutes of Health and University of Chicago have found a promising treatment method that in laboratory mice reduces the severity of skin and soft-tissue damage caused by USA300, the leading cause of community-associated Staphylococcus aureus infections in the United States.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.
› Verified 4 days ago
| Entity Name | Advanced Diagnostics Inc |
|---|---|
| Entity Type | Part B Supplier - Independent Diagnostic Testing Facility (idtf) |
| Entity Identifiers | NPI Number: 1487652442 PECOS PAC ID: 2769574912 Enrollment ID: O20070817000544 |
News Archive
Nearly 15,000 UK consumers answered questions about their hearing and their knowledge of hearing aids in the most comprehensive and largest survey ever undertaken in this field. The EuroTrak UK study will provide invaluable data for GPs, the NHS, Department of Health and the audiology profession. This study is now being publicised by The British Hearing Aid Manufacturers Association (BHAMA).
In a rare distinction for one university, neuroimaging world leaders and USC Professors Arthur Toga and Paul Thompson will receive two major research center awards to advance their exploration of the human brain.
Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.
Scientists from the National Institutes of Health and University of Chicago have found a promising treatment method that in laboratory mice reduces the severity of skin and soft-tissue damage caused by USA300, the leading cause of community-associated Staphylococcus aureus infections in the United States.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.
› Verified 4 days ago
| Entity Name | Carolina Cardiology And Vascular Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912400300 PECOS PAC ID: 3375899131 Enrollment ID: O20180709002680 |
News Archive
Nearly 15,000 UK consumers answered questions about their hearing and their knowledge of hearing aids in the most comprehensive and largest survey ever undertaken in this field. The EuroTrak UK study will provide invaluable data for GPs, the NHS, Department of Health and the audiology profession. This study is now being publicised by The British Hearing Aid Manufacturers Association (BHAMA).
In a rare distinction for one university, neuroimaging world leaders and USC Professors Arthur Toga and Paul Thompson will receive two major research center awards to advance their exploration of the human brain.
Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.
Scientists from the National Institutes of Health and University of Chicago have found a promising treatment method that in laboratory mice reduces the severity of skin and soft-tissue damage caused by USA300, the leading cause of community-associated Staphylococcus aureus infections in the United States.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.
› Verified 4 days ago
| Entity Name | Advanced Diagnostics Inc |
|---|---|
| Entity Type | Part B Supplier - Independent Diagnostic Testing Facility (idtf) |
| Entity Identifiers | NPI Number: 1487652442 PECOS PAC ID: 2769574912 Enrollment ID: O20201230001788 |
News Archive
Nearly 15,000 UK consumers answered questions about their hearing and their knowledge of hearing aids in the most comprehensive and largest survey ever undertaken in this field. The EuroTrak UK study will provide invaluable data for GPs, the NHS, Department of Health and the audiology profession. This study is now being publicised by The British Hearing Aid Manufacturers Association (BHAMA).
In a rare distinction for one university, neuroimaging world leaders and USC Professors Arthur Toga and Paul Thompson will receive two major research center awards to advance their exploration of the human brain.
Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.
Scientists from the National Institutes of Health and University of Chicago have found a promising treatment method that in laboratory mice reduces the severity of skin and soft-tissue damage caused by USA300, the leading cause of community-associated Staphylococcus aureus infections in the United States.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel P Bouknight, MD 1 Wellness Blvd Ste 106, Irmo, SC 29063-2872 Ph: (803) 888-2282 | Dr Daniel P Bouknight, MD 1 Wellness Blvd Ste 106, Irmo, SC 29063-2872 Ph: (803) 888-2282 |
News Archive
Nearly 15,000 UK consumers answered questions about their hearing and their knowledge of hearing aids in the most comprehensive and largest survey ever undertaken in this field. The EuroTrak UK study will provide invaluable data for GPs, the NHS, Department of Health and the audiology profession. This study is now being publicised by The British Hearing Aid Manufacturers Association (BHAMA).
In a rare distinction for one university, neuroimaging world leaders and USC Professors Arthur Toga and Paul Thompson will receive two major research center awards to advance their exploration of the human brain.
Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.
Scientists from the National Institutes of Health and University of Chicago have found a promising treatment method that in laboratory mice reduces the severity of skin and soft-tissue damage caused by USA300, the leading cause of community-associated Staphylococcus aureus infections in the United States.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.
› Verified 4 days ago
Dr. Joseph N Gabriel, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7182 Woodrow St Ste 200, Irmo, SC 29063 Phone: 803-749-1111 Fax: 803-749-0050 | |
Dr. Amjad Abdulrahman, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 7430 College St, Irmo, SC 29063 Phone: 803-732-4001 Fax: 803-799-1922 | |
Dr. John Gould Iii, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7430 College St, Irmo, SC 29063 Phone: 839-200-7810 Fax: 803-891-7085 | |
Dr. Melissa H Hummel, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7430 College St, Irmo, SC 29063 Phone: 839-200-7810 Fax: 803-891-7085 | |
Dr. Louis Carey Hite Iii, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7430 College St, Irmo, SC 29063 Phone: 839-200-7810 Fax: 803-891-7085 | |
Ian Smith, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Wellness Blvd Ste 109, Irmo, SC 29063 Phone: 803-749-1111 Fax: 803-749-0050 | |
Dr. Surbjinder S Guram, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Wellness Blvd Ste 109, Irmo, SC 29063 Phone: 803-749-1111 Fax: 803-749-0050 |